Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Goineau, Aurore ^a   Marchand, Virginie ^a   Rigaud, Jérome ^b   Bourdin, Sylvain ^a   Rio, Emmanuel ^a   Campion, Loic ^a   Bonnaud Antignac, Angélique ^a,b   Mahé, Marc André ^a   Supiot, Stéphane ^a  

^a Institut de Cancerologie de l'Quest Rene Gauducheau   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

IMRT; Prostate cancer; Quality of life

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DYSPNEA; FATIGUE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; NEPHROTOXICITY; PAIN; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; SOCIAL INTERACTION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; URINARY BLADDER; URINARY BLADDER DISEASES;

EID: 84874548606     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-53     Document Type: Article

References (39)

1. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974. 10.1001/jama.280.11.969, 9749478.
2. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012, 103:217-222. 10.1016/j.radonc.2012.01.007, 22341794.
3. Martin JM, Supiot S, Berthold DR. Pharmacotherapeutic management of locally advanced prostate cancer: current status. Drugs 2011, 71:1019-1041. 10.2165/11591500-000000000-00000, 21668040.
4. Lisbona A, Averbeck D, Supiot S, Delpon G, Ali D, Vinas F, Diana C, Murariu C, Lagrange J-L. IMRT combined to IGRT: increase of the irradiated volume. Consequences?. Cancer Radiother 2010, 14:563-570. 10.1016/j.canrad.2010.07.227, 20729117.
5. Crehange G, Mirjolet C, Gauthier M, Martin E, Truc G, Peignaux-Casasnovas K, Azelie C, Bonnetain F, Naudy S, Maingon P. Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. Radiother Oncol 2012, 103:244-246. 10.1016/j.radonc.2011.10.025, 22119374.
6. Pollack A, Zagars GK, Smith LG, Lee JJ, Von Eschenbach AC, Antolak JA, Starkschall G, Rosen I. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000, 18:3904-3911.
7. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010, 28:1106-1111. 10.1200/JCO.2009.25.8475, 2834463, 20124169.
8. Beckendorf V, Guerif S, Le Prisé E, Cosset J-M, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud J-M, Maingon P, Hannoun-Levi J-M, Malissard L, Simon J-M, Pommier P, Hay M, Dubray B, Lagrange J-L, Luporsi E, Bey P. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011, 80:1056-1063. 10.1016/j.ijrobp.2010.03.049, 21147514.
9. Peeters STH, Heemsbergen WD, Koper PCM, Van Putten WLJ, Slot A, Dielwart MFH, Bonfrer JMG, Incrocci L, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996. 10.1200/JCO.2005.05.2530, 16648499.
10. De Meerleer GO, Vakaet LA, De Gersem WR, De Wagter C, De Naeyer B, De Neve W. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 2000, 47:639-648. 10.1016/S0360-3016(00)00419-3, 10837946.
11. Peeters STH, Heemsbergen WD, Van Putten WLJ, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PCM. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005, 61:1019-1034. 10.1016/j.ijrobp.2004.07.715, 15752881.
12. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006, 176:1415-1419. 10.1016/j.juro.2006.06.002, 16952647.
13. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:1124-1129. 10.1016/j.ijrobp.2007.11.044, 18313526.
14. Niezgoda HE, Pater JL. A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res 1993, 2:319-325. 10.1007/BF00449426, 8136796.
15. Ferrer M, Suárez JF, Guedea F, Fernández P, Macías V, Mariño A, Hervas A, Herruzo I, Ortiz MJ, Villavicencio H, Craven-Bratle J, Garin O, Aguiló F. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:421-432. 10.1016/j.ijrobp.2007.12.024, 18325680.
16. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261. 10.1056/NEJMoa074311, 18354103.
17. Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. J Urol 2004, 172:515-519. 10.1097/01.ju.0000129236.56712.e7, 15247718.
18. Lips IM, Van Gils CH, Van der Heide UA, Kruger AEB, Van Vulpen M. Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification. BJU Int 2009, 103:762-767. 10.1111/j.1464-410X.2008.08117.x, 18990145.
19. Namiki S, Ishidoya S, Ito A, Tochigi T, Numata I, Narazaki K, Yamada S, Takai Y, Arai Y. Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer. Jpn J Clin Oncol 2009, 39:732-738. 10.1093/jjco/hyp086, 19666904.
20. Odrazka K, Dolezel M, Vanasek J, Vaculikova M, Zouhar M, Sefrova J, Paluska P, Vosmik M, Kohlova T, Kolarova I, Macingova Z, Navratil P, Brodak M, Prosvic P. Time course of late rectal toxicity after radiation therapy for prostate cancer. Prostate Cancer Prostatic Dis 2010, 13:138-143. 10.1038/pcan.2009.56, 20038960.
21. Sharma NK, Li T, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 80:437-444. 10.1016/j.ijrobp.2010.02.040, 21050673.
22. Marchand V, Bourdin S, Charbonnel C, Rio E, Munos C, Campion L, Bonnaud-Antignac A, Lisbona A, Mahé M-A, Supiot S. No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010, 77:1053-1059. 10.1016/j.ijrobp.2009.06.024, 19880259.
23. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277:1445-1451. 10.1001/jama.1997.03540420041027, 9145716.
24. Delpon G, Llagostera C, Le Blanc M, Rio E, Supiot S, Mahé M-A, Lisbona A. [Use of IGRT for prostate cancers (OBI-CBCT Varian, ExacTrac BrainLAB and MVCT TomoTherapy)]. Cancer Radiother 2009, 13:399-407. 10.1016/j.canrad.2009.06.001, 19640764.
25. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, De Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376. 10.1093/jnci/85.5.365, 8433390.
26. Fayers P, Bottomley A. Quality Of life research within the EORTC-the EORTC QLQ-C30. European organisation for research and treatment of cancer. Eur J Cancer 2002, 38(Suppl 4):S125-S133.
27. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16:139-144.
28. Grant JD, Litwin MS, Kwan L, Lee SP, Steinberg ML, King CR. Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study. J Urol 2011, 185:1674-1680. 10.1016/j.juro.2010.12.092, 21419449.
29. Chen RC, Zhang Y, Chen M-H, McMahon E, Loffredo M, McPherson CP, Nguyen AU, Nguyen PL, D'Amico AV. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial. BJU Int 2012, 110(11):1690-1695. 10.1111/j.1464-410X.2012.11117.x, 22502770.
30. Namiki S, Ishidoya S, Tochigi T, Kawamura S, Kuwahara M, Terai A, Yoshimura K, Numata I, Satoh M, Saito S, Takai Y, Yamada S, Arai Y. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy. Jpn J Clin Oncol 2006, 36:224-230. 10.1093/jjco/hyl002, 16537689.
31. Odrazka K, Dolezel M, Vanasek J, Vaculikova M, Zouhar M, Sefrova J, Paluska P, Vosmik M, Kohlova T, Kolarova I, Navratil P, Brodak M, Prosvic P, Hoffmann P. Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer: impact of previous surgery for benign prostatic hyperplasia. Int J Urol 2010, 17:784-790. 10.1111/j.1442-2042.2010.02592.x, 20604816.
32. Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys 2010, 82(1):235-241.
33. Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, Cox B, Zelefsky MJ. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011, 117:1429-1437. 10.1002/cncr.25467, 21425143.
34. Choo R, Long J, Gray R, Morton G, Gardner S, Danjoux C. Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. Support Care Cancer 2010, 18:715-722. 10.1007/s00520-009-0675-6, 19506916.
35. Forbat L, White I, Marshall-Lucette S, Kelly D. Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer. BJU Int 2011, 109(1):98-103.
36. Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, Bristow R, Chung P, Ménard C, Milosevic M, Warde P, Catton C. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2011, 81:e415-e421. 10.1016/j.ijrobp.2011.01.024, 21477939.
37. Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai K-H, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol 2012, 13:1260-1270. 10.1016/S1470-2045(12)70423-0, 23151431.
38. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Eble MJ. Low-grade toxicity after conformal radiation therapy for prostate cancer-impact of bladder volume. Int J Radiat Oncol Biol Phys 2006, 64:835-841. 10.1016/j.ijrobp.2005.09.003, 16289911.
39. Eade TN, Guo L, Forde E, Vaux K, Vass J, Hunt P, Kneebone A. Image-guided dose-escalated intensity-modulated radiation therapy for prostate cancer: treating to doses beyond 78 Gy. BJU Int 2011, 109(11):1655-1660.